Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

With a market cap of $62.4 billion, Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...

Along with first-line PDL1-positive NSCLC, Libtayo is also used to treat two forms of skin cancer – cutaneous squamous cell carcinoma and basal cell carcinoma. Merck claims adjuvant win in melanoma ...

Regeneron and Sanofi’s PD-1 inhibitor Libtayo will be tested in tandem with a cancer vaccine developed by BioNTech in melanoma in people who have failed treatment with other checkpoint inhibitors.

today announced that Ig - Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data ...

A new study suggests that targeting the protein alpha-synuclein could be a possible new target for treating melanoma.

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for ...